novo nordisk patent semaglutide to lose blockbuster drug over small fee What is the patent landscape

Compounded GLP-1 medications are not authorised in Canada

Tirzepatide, sold under the brand name Mounjaro, is a dual-action medication that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors

Individual experiences vary based on body chemistry, diet, and geneticsnot the source of the medication

How the cagrilintide + retatrutide stack compares Feature Components Cagrilintide + Retatrutide Cagrilintide + Retatrutide CagriSema (Cag + Sema) Cagrilintide + Semaglutide Retatrutide Alone Retatrutide only Feature Receptor coverage Cagrilintide + Retatrutide AMY + GLP-1R + GIPR + GCGR CagriSema (Cag + Sema) AMY + GLP-1R Retatrutide Alone GLP-1R + GIPR + GCGR Feature Combination clinical data Cagrilintide + Retatrutide None (speculative) CagriSema (Cag + Sema) Phase 3 REDEFINE-1: ~22.7% at 68 weeks Retatrutide Alone Not a combination

Clinicians and coaches who get itbecause theyve lived it